Active Ingredient(s): Afamelanotide
FDA Approved: * October 8, 2019
Pharm Company: * CLIVUNEL INC
Category: Genetic Disorders

Afamelanotide, sold under the brand name Scenesse, is a synthetic peptide and analogue of α-melanocyte stimulating hormone used to prevent skin damage from the sun in people with erythropoietic protoporphyria in the European Union since January 2015, and the United States since October 2019. As a medication it is administered in subcutaneous implant form; the implant lasts for two months.[medical citation needed] The U.S. Food and Drug Administration (FDA) considers it to... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Scenesse 16 mg/16mg Subcutaneous Implant
NDC: 73372-0116
Clinuvel Inc.
Scenesse 16 mg/16mg Subcutaneous Implant
NDC: 73850-0116
Csm Clinical Supplies Management Europe Gmbh